Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 51.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,983 shares of the specialty pharmaceutical company's stock after selling 40,653 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.12% of Collegium Pharmaceutical worth $1,117,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in COLL. Principal Financial Group Inc. increased its position in shares of Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock worth $29,974,000 after acquiring an additional 5,464 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 4.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company's stock valued at $14,741,000 after acquiring an additional 16,655 shares in the last quarter. Royce & Associates LP raised its position in shares of Collegium Pharmaceutical by 11.0% in the 4th quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after purchasing an additional 33,674 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after purchasing an additional 175,892 shares in the last quarter.

Remove Ads

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now directly owns 124,421 shares of the company's stock, valued at $3,732,630. This trade represents a 1.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock valued at $3,243,594 over the last 90 days. 3.98% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

COLL has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Finally, Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.39 on Wednesday, reaching $29.78. The company's stock had a trading volume of 46,389 shares, compared to its average volume of 436,639. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a market capitalization of $937.78 million, a P/E ratio of 12.81 and a beta of 0.99. The stock has a 50-day moving average price of $30.21 and a 200-day moving average price of $32.29. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.